Table 2.
Clinical trials with LAG‐3
| Year | Drug | Phase | Company | Type | Objective | Clinical trial.gov identifier |
|---|---|---|---|---|---|---|
| 2006 | IMP321 | I | Immutep S.A. | sLAG‐3 | IMP321 given alone or with a reference flu antigen | NCT00354263 |
| 2006 | IMP321 | I | Immutep S.A. | sLAG‐3 | IMP321 combined with a hepatitis B antigen | NCT00354861 |
| 2006 | IMP321 | I | Immutep S.A. | sLAG‐3 | IMP321 metastatic breast carcinoma receiving first line paclitaxel | NCT00349934 |
| 2006 | IMP321 | I | Immutep S.A. | sLAG‐3 | IMP321 in metastatic renal cell carcinoma | NCT00351949 |
| 2008 | IMP321 | I | Immutep S.A. | sLAG‐3 | IMP321 and gemcitabine in advanced pancreatic cancer | NCT00732082 |
| 2015 | IMP321 | II | Immutep S.A. | sLAG‐3 | Adjunctive IMP321 to paclitaxel in metastatic breast carcinoma | NCT02614833 |
| 2013 | BMS‐986016 | I | BMS | Anti‐LAG‐3 | The safety of anti‐LAG‐3 alone or with anti‐PD‐1 in solid tumors | NCT01968109 |
| 2014 | BMS‐986016 | I | BMS | Anti‐LAG‐3 | The safety of anti‐LAG‐3 in hematological malignant tumors | NCT02061761 |
| 2016 | BMS‐986016 | I | BMS | Anti‐LAG‐3 | Anti‐LAG‐3 or urelumab alone or with nivolumab in recurrent glioblastoma | NCT02658981 |
| 2014 | GSK2831781 | I | GSK | Anti‐LAG‐3 | GSK2831781 in healthy people and patients with plaque psoriasis | NCT02195349 |